Pathogenesis of autoimmune diseases: Antibodies against transglutaminase, peptidylarginine deiminase and protein-bound citrulline in primary Sjögren's syndrome, multiple sclerosis and Alzheimer's disease

Scandinavian Journal of Immunology

Volumn 67, Issue 6, 2008, Pages 626-631

  Bodil Roth, E ^a,b   Theander, E ^a   Londos, E ^b   Sandberg Wollheim, M ^a   Larsson, A ^c   Sjoberg K ^b   Stenberg, P ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c MALMÖ UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CITRULLINATED PROTEIN ANTIBODY; CITRULLINE; GLIADIN; PEPTIDYLARGININE DEIMINASE ANTIBODY; PROTEIN ANTIBODY; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE ANTIBODY;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED STUDY; ENZYME SUBSTRATE COMPLEX; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME;

ALZHEIMER DISEASE; AUTOANTIBODIES; AUTOIMMUNE DISEASES; CITRULLINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GTP-BINDING PROTEINS; HUMANS; HYDROLASES; MULTIPLE SCLEROSIS; PROTEINS; SJOGREN'S SYNDROME; TRANSGLUTAMINASES;

EID: 43549086375     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2008.02115.x     Document Type: Article

References (31)

1. Fox PC. Autoimmune diseases and Sjogren's syndrome: an autoimmune exocrinopathy. Ann N Y Acad Sci 2007 1098 : 15 21.
2. Committee TADC. Progress in Autoimmune Disease Research: A Report to Congress. Bethesda, MD : U.S.Department of Health and Human Service, National Institutes of Health, National Institute of Allergy and Infectious Diseases (Access at http://www.niaid.nih.gov/publications/pdf/ADCCFinal.pdf), 2005.
3. Dieterich W, Ehnis T, Bauer M et al. Identification of tissue transglutaminase as the autoantigen of celiac disease. Nat Med 1997 3 : 797 801.
4. Larre C, Chiarello M, Blanloeil Y, Chenu M, Gueguen J. Gliadin modifications catalysed by guinea pig liver transglutaminase. J Food Biochem 1993 112 : 267 82.
5. Sjostrom H, Lundin KE, Molberg O et al. Identification of a gliadin T-cell epitope in coeliac disease: general importance of gliadin deamidation for intestinal T-cell recognition. Scand J Immunol 1998 48 : 111 5.
6. Stenberg P, Roth EB, Sjoberg K. Transglutaminase and the pathogenesis of coeliac disease. Eur J Intern Med 2008 19 : 83 91.
7. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family of citrullinating enzymes: genes, features and involvement in disease. Bioessays 2003 25 : 1106 18.
8. van Venrooij WJ, Hazes JM, Visser H. Anticitrullinated protein/peptide antibody and its role in the diagnosis and prognosis of early rheumatoid arthritis. Neth J Med 2002 60 : 383 8.
9. Roth EB, Stenberg P, Book C, Sjoberg K. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis - new pathways to epitope spreading. Clin Exp Rheumatol 2006 24 : 12 8.
10. Nissinen R, Paimela L, Julkunen H et al. Peptidylarginine deiminase, the arginine to citrulline converting enzyme is frequently recognized by sera of patients with rheumatoid arthritis, systemic lupus erythematosus and primary Sjogren syndrome. Scand J Rheumatol 2003 32 : 337 42.
11. Takizawa Y, Sawada T, Suzuki A, Yamada R, Inoue T, Yamamoto K. Peptidylarginine deiminase 4 (PADI4) identified as a conformation-dependent autoantigen in rheumatoid arthritis. Scand J Rheumatol 2005 34 : 212 5.
12. Halvorsen EH, Pollmann S, Gilboe IM et al. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann Rheum Dis 2008 67 : 414 7.
13. Kamali S, Polat NG, Kasapoglu E et al. Anti-CCP and antikeratin antibodies in rheumatoid arthritis, primary Sjogren's syndrome, and Wegener's granulomatosis. Clin Rheumatol 2005 24 : 673 6.
14. Gottenberg JE, Mignot S, Nicaise-Rolland P et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjogren's syndrome. Ann Rheum Dis 2005 64 : 114 7.
15. Moscarello MA, Pritzker L, Mastronardi FG, Wood DD. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J Neurochem 2002 81 : 335 43.
16. Raijmakers R, Vogelzangs J, Raats J et al. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J Comp Neurol 2006 498 : 217 26.
17. van Strien M, Drukarch B, Bol J, Brevé J, van Dam A-M. Tissue transglutaminase in multiple sclerosis: a novel therapeutic target? 9th International Conference on Transglutaminases and Protein Cross Linking, 2007, p. 83.
18. Ishigami A, Ohsawa T, Hiratsuka M et al. Abnormal accumulation of citrullinated proteins catalyzed by peptidylarginine deiminase in hippocampal extracts from patients with Alzheimer's disease. J Neurosci Res 2005 80 : 120 8.
19. Muma NA. Transglutaminase is linked to neurodegenerative diseases. J Neuropathol Exp Neurol 2007 66 : 258 63.
20. Truedsson L, Sjöholm A, Sturfeldt G. Complement activation rheumatoid factors in rheumatoid arthritis studies by hemolysis in gel: relation to antibody class and response to treatment with podophyllotoxin derivates. Clin Exp Rheumatol 1984 3 : 29 37.
21. Vitali C, Bombardieri S, Jonsson R et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002 61 : 554 8.
22. McDonald WI, Compston A, Edan G et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 50 : 121 7.
23. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984 34 : 939 44.
24. Chorzelski TP, Sulej J, Tchorzewska H, Jablonska S, Beutner EH, Kumar V. IgA class endomysium antibodies in dermatitis herpetiformis and coeliac disease. Ann N Y Acad Sci 1983 420 : 325 34.
25. Roth EB, Sjoberg K, Stenberg P. Biochemical and immuno-pathological aspects of tissue transglutaminase in coeliac disease. Autoimmunity 2003 36 : 221 6.
26. Agardh D, Roth B, Lernmark A, Stenberg P. Calcium activation of tissue transglutaminase in radioligand binding and enzyme-linked autoantibody immunoassays in childhood celiac disease. Clin Chim Acta 2005 358 : 95 103.
27. Bowman SJ, Ibrahim GH, Holmes G, Hamburger J, Ainsworth JR. Estimating the prevalence among Caucasian women of primary Sjogren's syndrome in two general practices in Birmingham, UK. Scand J Rheumatol 2004 33 : 39 43.
28. Trontzas P, Andrianakos A, Miyakis S et al. Seronegative spondyloarthropathies in Greece: a population-based study of prevalence, clinical pattern, and management. The ESORDIG study. Clin Rheumatol 2005 24 : 583 9.
29. Vitali C, Bombardieri S, Moutsopoulos HM et al. Preliminary criteria for the classification of Sjogren's syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum 1993 36 : 340 7.
30. Iltanen S, Collin P, Korpela M et al. Celiac disease and markers of celiac disease latency in patients with primary Sjogren's syndrome. Am J Gastroenterol 1999 94 : 1042 6.
31. Vermes I, Steur EN, Jirikowski GF, Haanen C. Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov Disord 2004 19 : 1252 4.